Massive study follows 10,000+ patients to see who sticks with Scarred-Lung drugs

This study aims to understand how long patients with lung scarring diseases like Idiopathic Pulmonary Fibrosis (IPF) continue taking their antifibrotic medications in real-world French healthcare settings. It will follow over 10,000 patients who started treatment between 2018 and 2022 to see what percentage are still taking their medication 30 months later and identify factors linked to stopping treatment. The goal is to gather knowledge about treatment patterns to find areas where patient care and support might be improved.